Bioblast Pharma Ltd Company Profile (NASDAQ:ORPN)

About Bioblast Pharma Ltd

Bioblast Pharma Ltd logoBioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich's ataxia) and BBrm-02. The Company's product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ORPN
  • CUSIP:
Key Metrics:
  • Previous Close: $1.04
  • 50 Day Moving Average: $1.23
  • 200 Day Moving Average: $1.45
  • 52-Week Range: $0.92 - $7.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.42
  • P/E Growth: 0.00
  • Market Cap: $17.05M
  • Outstanding Shares: 16,391,000
  • Beta: 0.16
Profitability:
  • Return on Equity: -52.90%
  • Return on Assets: -46.88%
Debt:
  • Current Ratio: 6.67%
  • Quick Ratio: 6.67%
Additional Links:
Companies Related to Bioblast Pharma Ltd:

Analyst Ratings

Consensus Ratings for Bioblast Pharma Ltd (NASDAQ:ORPN) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.00 (1,726.92% upside)

Analysts' Ratings History for Bioblast Pharma Ltd (NASDAQ:ORPN)
Show:
DateFirmActionRatingPrice TargetDetails
10/24/2016Roth CapitalSet Price TargetBuy$15.00View Rating Details
7/11/2016Rodman & RenshawReiterated RatingBuyView Rating Details
1/28/2016HC WainwrightInitiated CoverageBuy$25.00View Rating Details
11/27/2015Oppenheimer Holdings, Inc.Reiterated RatingOutperform$32.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Bioblast Pharma Ltd (NASDAQ:ORPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/24/2017        
8/25/2016Q2($0.27)($0.22)ViewN/AView Earnings Details
5/25/2016Q1($0.29)($0.32)ViewN/AView Earnings Details
2/23/2016Q4($0.25)($0.34)ViewN/AView Earnings Details
11/17/2015Q3($0.29)($0.25)ViewN/AView Earnings Details
8/21/2015Q2($0.28)($0.26)ViewN/AView Earnings Details
5/19/2015Q115($0.25)($0.23)ViewN/AView Earnings Details
2/17/2015Q414($0.16)($0.22)ViewN/AView Earnings Details
11/21/2014($0.09)($0.16)ViewN/AView Earnings Details
8/29/2014Q214($0.09)($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bioblast Pharma Ltd (NASDAQ:ORPN)
Current Year EPS Consensus Estimate: $-0.82 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.33)($0.26)($0.30)
Q2 20161($0.33)($0.33)($0.33)
Q3 20161($0.22)($0.22)($0.22)
Q4 20161($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bioblast Pharma Ltd (NASDAQ:ORPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bioblast Pharma Ltd (NASDAQ:ORPN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Bioblast Pharma Ltd (NASDAQ:ORPN)
DateHeadline
News IconBio Blast Pharma Ltd ORPN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:ORPN)
www.bioportfolio.com - February 26 at 12:05 PM
News IconBio Blast Pharma Ltd. (NASDAQ:ORPN) Daily Sentiment Score At 0 - Stock Observer (NASDAQ:ORPN)
www.thestockobserver.com - February 25 at 6:42 PM
News IconBioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results - P&T Community (NASDAQ:ORPN)
www.ptcommunity.com - February 25 at 6:42 PM
us.rd.yahoo.com logoBioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results (NASDAQ:ORPN)
us.rd.yahoo.com - February 24 at 8:45 AM
sg.finance.yahoo.com logoBio Blast reports 4Q loss (NASDAQ:ORPN)
sg.finance.yahoo.com - February 24 at 8:45 AM
News IconBroker Changes For Bio Blast Pharma Ltd. (ORPN) - NewsDen (NASDAQ:ORPN)
newsden.net - February 23 at 9:15 AM
News IconBio Blast Pharma Ltd. (NASDAQ:ORPN) Quarterly EPS At $-0.16 - Stock Observer (NASDAQ:ORPN)
www.thestockobserver.com - February 21 at 5:50 PM
News IconBio Blast Pharma Ltd. (NASDAQ:ORPN) Bearish Target At $9 - Stock Observer (NASDAQ:ORPN)
www.thestockobserver.com - February 18 at 6:14 PM
News IconBio Blast Pharma Ltd. (NASDAQ:ORPN) Daily Sentiment Score At ... - Stock Observer (NASDAQ:ORPN)
www.thestockobserver.com - February 10 at 1:15 AM
kcregister.com logoBioblast Pharma provide new clinical and development updates for trehalose 90 mg/mL solution for OPMD - KC Register (NASDAQ:ORPN)
www.kcregister.com - February 3 at 1:01 AM
News IconSignal Watch: Checking the Numbers for Bio Blast Pharma Ltd. (ORPN) - Sherwood Daily (NASDAQ:ORPN)
sherwooddaily.com - February 3 at 1:01 AM
us.rd.yahoo.com logoBioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative Diseases (NASDAQ:ORPN)
us.rd.yahoo.com - February 2 at 7:59 PM
us.rd.yahoo.com logo4:02 pm Bio Blast Pharma announces clinical update related to its proprietary intravenous (:IV) form of trehalose 90 mg/mL solution, which is being evaluated as a potential therapeutic, initially for oculopharyngeal muscular dystrophy (NASDAQ:ORPN)
us.rd.yahoo.com - February 2 at 7:59 PM
News IconTechnical Study: Following Indicators for Bio Blast Pharma Ltd. (ORPN) - Sherwood Daily (NASDAQ:ORPN)
sherwooddaily.com - February 1 at 8:12 PM
News IconIncrease in Volatility Draws Attention to Shares of Bioblast Pharma Ltd. (NASDAQ:ORPN) - Wall Street Beacon (NASDAQ:ORPN)
wsbeacon.com - February 1 at 8:12 PM
finance.yahoo.com logoBioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and ... - Yahoo Finance (NASDAQ:ORPN)
finance.yahoo.com - February 1 at 8:12 PM
News IconTechnical Focus: Williams %R, ADX, and CCI Levels for Bio Blast Pharma Ltd. (ORPN) - Sherwood Daily (NASDAQ:ORPN)
sherwooddaily.com - February 1 at 1:06 AM
News IconReady for an Upsurge? Analysts Chime in on Bioblast Pharma Ltd. (NASDAQ:ORPN) - Prospect Journal (NASDAQ:ORPN)
prospectjournal.com - January 31 at 5:49 AM
News IconCheap Stock Alert on Bioblast Pharma Ltd. (NASDAQ:ORPN) - Prospect Journal (NASDAQ:ORPN)
prospectjournal.com - January 31 at 12:48 AM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Bioblast Pharma Ltd. (NASDAQ:ORPN) - Nelson Research (NASDAQ:ORPN)
nelsonobserver.com - January 29 at 8:57 AM
News IconAverage Directional Index Review for Bio Blast Pharma Ltd. (ORPN) - Sherwood Daily (NASDAQ:ORPN)
sherwooddaily.com - January 28 at 5:30 AM
News IconHigh Volatility Creating Buzz Mid-Session For Bioblast Pharma Ltd. (NASDAQ:ORPN) - Wall Street Beacon (NASDAQ:ORPN)
wsbeacon.com - January 28 at 5:30 AM
News IconWorth Watching Stock: Bioblast Pharma Ltd (NASDAQ:ORPN ... - Post Registrar (NASDAQ:ORPN)
postregistrar.com - January 28 at 5:30 AM
News IconStock Spotter: Review on Technical Levels for Bio Blast Pharma Ltd. (ORPN) - Sherwood Daily (NASDAQ:ORPN)
sherwooddaily.com - January 27 at 5:22 AM
finance.yahoo.com logoBioblast Pharma to Host Key Opinion Leader Lunch Focused on Orphan Neurological Diseases on February 2 (NASDAQ:ORPN)
finance.yahoo.com - January 27 at 12:21 AM
investornewswire.com logoStrong Sell Recommendations Of Bio Blast Pharma Ltd. (NASDAQ:ORPN) At 0 - Investor Newswire (NASDAQ:ORPN)
www.investornewswire.com - January 24 at 12:25 AM
News IconMarket Review: Indicator Watch for Bio Blast Pharma Ltd. (ORPN) - Sherwood Daily (NASDAQ:ORPN)
sherwooddaily.com - January 24 at 12:25 AM
News IconPriming The Pump: Stock Volatility Spotted in Bioblast Pharma Ltd. (NASDAQ:ORPN) - Wall Street Beacon (NASDAQ:ORPN)
wsbeacon.com - January 24 at 12:25 AM
News IconTrump Sworn In as S&P Declined, How Did this Stock Perform This Week: Bioblast Pharma Ltd. (NASDAQ:ORPN) - Aiken Advocate (NASDAQ:ORPN)
aikenadvocate.com - January 22 at 11:54 PM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Bioblast Pharma Ltd. (NASDAQ:ORPN) - Wall Street Beacon (NASDAQ:ORPN)
wsbeacon.com - January 22 at 11:54 PM
News IconA Keen Look at These Shares: Bioblast Pharma Ltd. (NASDAQ:ORPN) - Prospect Journal (NASDAQ:ORPN)
prospectjournal.com - January 21 at 7:57 AM
News IconAmplified Volatility Spotted in Shares of Bioblast Pharma Ltd. (NASDAQ:ORPN) - Wall Street Beacon (NASDAQ:ORPN)
wsbeacon.com - January 21 at 7:57 AM
News IconIs There a Spark Ahead for Bioblast Pharma Ltd. (NASDAQ:ORPN) - Prospect Journal (NASDAQ:ORPN)
prospectjournal.com - January 19 at 11:44 PM
finance.yahoo.com logoBioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study (NASDAQ:ORPN)
finance.yahoo.com - January 19 at 11:44 PM
News IconQuick on the Draw, Shares Galloping Higher Mid-Day: Bioblast Pharma Ltd. (NASDAQ:ORPN) - Aiken Advocate (NASDAQ:ORPN)
aikenadvocate.com - January 19 at 12:40 AM
News IconPeculiar Activity & Volume Spotted in Shares of Bioblast Pharma Ltd. (NASDAQ:ORPN) - Aiken Advocate (NASDAQ:ORPN)
aikenadvocate.com - January 19 at 12:40 AM
News IconTechnical Update on Shares of Bio Blast Pharma Ltd. (ORPN) - Sherwood Daily (NASDAQ:ORPN)
sherwooddaily.com - January 19 at 12:40 AM
News IconCan This Stock Pick Up Any Momentum: Bioblast Pharma Ltd. (NASDAQ:ORPN) - Prospect Journal (NASDAQ:ORPN)
prospectjournal.com - January 19 at 12:40 AM
finance.yahoo.com logo8:01 am Bio Blast Pharma announces results of a 6-month open label Phase 2a study that also included an additional six-month follow-up period investigating trehalose in patients with Spinocerebellar Ataxia Type 3 (NASDAQ:ORPN)
finance.yahoo.com - January 18 at 7:39 PM
News IconInvestor Guide: Checking on Indicators for Bio Blast Pharma Ltd. (ORPN) - Sherwood Daily (NASDAQ:ORPN)
sherwooddaily.com - January 18 at 8:51 AM
News IconKnuckling Down on Shares of Bioblast Pharma Ltd. (NASDAQ:ORPN) - Prospect Journal (NASDAQ:ORPN)
prospectjournal.com - January 18 at 8:51 AM
finance.yahoo.com logoBioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3) (NASDAQ:ORPN)
finance.yahoo.com - January 18 at 8:51 AM
News IconCan This Stock Hit on All Cylinders And Achieve Projections: Bioblast Pharma Ltd. (NASDAQ:ORPN) - Prospect Journal (NASDAQ:ORPN)
prospectjournal.com - January 16 at 7:35 PM
News IconKeen Investors Taking a Look at Bioblast Pharma Ltd. (NASDAQ:ORPN) - Prospect Journal (NASDAQ:ORPN)
prospectjournal.com - January 16 at 7:35 PM
News IconBio Blast Pharma Ltd. (NASDAQ:ORPN) Daily Sentiment Score At 0.31 - Stock Observer (NASDAQ:ORPN)
www.thestockobserver.com - January 12 at 7:41 PM
News IconStock Edging Lower Out Of The Gate: Bioblast Pharma Ltd. (NASDAQ:ORPN) - Wall Street Beacon (NASDAQ:ORPN)
wsbeacon.com - January 12 at 7:41 PM
News IconBio Blast Pharma Ltd ORPN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ORPN)
www.bioportfolio.com - January 12 at 5:48 AM
News IconCan This Stock Make a Ripple in the Market: Bioblast Pharma Ltd. (NASDAQ:ORPN) - Prospect Journal (NASDAQ:ORPN)
prospectjournal.com - January 12 at 12:46 AM
News IconBargain Hunters Should Take a Look at Bioblast Pharma Ltd. (NASDAQ:ORPN) - Prospect Journal (NASDAQ:ORPN)
prospectjournal.com - January 10 at 12:48 AM
News IconNear-Term, Can This Stock Move the Needle: Bioblast Pharma Ltd. (NASDAQ:ORPN) - Prospect Journal (NASDAQ:ORPN)
prospectjournal.com - January 4 at 7:52 PM

Social

What is Bioblast Pharma Ltd's stock symbol?

Bioblast Pharma Ltd trades on the NASDAQ under the ticker symbol "ORPN."

Where is Bioblast Pharma Ltd's stock going? Where will Bioblast Pharma Ltd's stock price be in 2017?

2 brokers have issued 12-month price objectives for Bioblast Pharma Ltd's stock. Their predictions range from $15.00 to $23.00. On average, they anticipate Bioblast Pharma Ltd's share price to reach $19.00 in the next twelve months.

When will Bioblast Pharma Ltd announce their earnings?

Bioblast Pharma Ltd is scheduled to release their next quarterly earnings announcement on Friday, February, 24th 2017.

Who owns Bioblast Pharma Ltd stock?

Bioblast Pharma Ltd's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.73%).

Who bought Bioblast Pharma Ltd stock? Who is buying Bioblast Pharma Ltd stock?

Bioblast Pharma Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy Bioblast Pharma Ltd stock?

Shares of Bioblast Pharma Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bioblast Pharma Ltd stock cost?

One share of Bioblast Pharma Ltd stock can currently be purchased for approximately $1.04.

Bioblast Pharma Ltd (NASDAQ:ORPN) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Bioblast Pharma Ltd (NASDAQ:ORPN)

Earnings History Chart

Earnings by Quarter for Bioblast Pharma Ltd (NASDAQ:ORPN)

Dividend History Chart

Dividend Payments by Quarter for Bioblast Pharma Ltd (NASDAQ:ORPN)

Last Updated on 2/27/2017 by MarketBeat.com Staff